

# Michael M Tunney

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5952947/publications.pdf>

Version: 2024-02-01

69  
papers

2,986  
citations

218592

26  
h-index

175177

52  
g-index

69  
all docs

69  
docs citations

69  
times ranked

3782  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Chryseobacterium mucilaginosa</i> is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. <i>European Respiratory Journal</i> , 2022, 59, 2101293.	3.1	60
2	The EXIMIOUS project—Mapping exposure-induced immune effects: connecting the exposome and the immunome. <i>Environmental Epidemiology</i> , 2022, 6, e193.	1.4	8
3	The Effects of <i>Agrimonia pilosa</i> Ledeb, <i>Anemone chinensis</i> Bunge, and <i>Smilax glabra</i> Roxb on Broiler Performance, Nutrient Digestibility, and Gastrointestinal Tract Microorganisms. <i>Animals</i> , 2022, 12, 1110.	1.0	1
4	Taxonomic position, antibiotic resistance and virulence factor production by <i>Stenotrophomonas</i> isolates from patients with cystic fibrosis and other chronic respiratory infections. <i>BMC Microbiology</i> , 2022, 22, 129.	1.3	8
5	Characterization of Bacteria Using Surface-Enhanced Raman Spectroscopy (SERS): Influence of Microbiological Factors on the SERS Spectra. <i>Analytical Chemistry</i> , 2022, 94, 9327-9335.	3.2	19
6	Efficacy and safety of TOBI Podhaler in <i>Pseudomonas aeruginosa</i> -infected bronchiectasis patients: iBEST study. <i>European Respiratory Journal</i> , 2021, 57, 2001451.	3.1	30
7	Development of a core outcome set for clinical trials aimed at improving antimicrobial stewardship in care homes. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 52.	1.5	2
8	Anti-biofilm activity of murepavadin against cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2578-2585.	1.3	12
9	Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 747-753.	0.3	30
10	Murepavadin antimicrobial activity against and resistance development in cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 984-992.	1.3	21
11	Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 764585.	1.8	1
12	Composition of airway bacterial community correlates with chest HRCT in adults with bronchiectasis. <i>Respirology</i> , 2020, 25, 64-70.	1.3	6
13	Influence of azithromycin and allograft rejection on the post-lung transplant microbiota. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 176-183.	0.3	22
14	Susceptibility of <i>Pseudomonas aeruginosa</i> Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	24
15	Extracellular polymeric substance-mediated tolerance of <i>Pseudomonas aeruginosa</i> biofilms to atmospheric pressure nonthermal plasma treatment. <i>Plasma Processes and Polymers</i> , 2020, 17, 2000108.	1.6	4
16	Multiple breath washout in bronchiectasis clinical trials: is it feasible?. <i>ERJ Open Research</i> , 2020, 6, 00363-2019.	1.1	5
17	Developing evidence-based guidance for assessment of suspected infections in care home residents. <i>BMC Geriatrics</i> , 2020, 20, 59.	1.1	8
18	Lung function and microbiota diversity in cystic fibrosis. <i>Microbiome</i> , 2020, 8, 45.	4.9	138

#	ARTICLE	IF	CITATIONS
19	Draft Genome Sequence of a Haemophilus parainfluenzae Strain Isolated from a Patient with Chronic Obstructive Pulmonary Disease. Microbiology Resource Announcements, 2020, 9, .	0.3	0
20	A multifaceted intervention to reduce antimicrobial prescribing in care homes: a non-randomised feasibility study and process evaluation. Health Services and Delivery Research, 2020, 8, 1-150.	1.4	0
21	A general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans. Journal of Biological Chemistry, 2019, 294, 13248-13268.	1.6	27
22	Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). Pulmonary Pharmacology and Therapeutics, 2019, 58, 101834.	1.1	8
23	Interventions to Improve Antimicrobial Stewardship for Older People in Care Homes: A Systematic Review. Drugs and Aging, 2019, 36, 355-369.	1.3	19
24	Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 808-816.	0.3	19
25	British Thoracic Society Guideline for bronchiectasis in adults. Thorax, 2019, 74, 1-69.	2.7	291
26	Multifaceted intervention to Reduce Antimicrobial Prescribing in Care Homes: a process evaluation of a UK-based non-randomised feasibility study. BMJ Open, 2019, 9, e032185.	0.8	8
27	Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens. Respiratory Research, 2019, 20, 267.	1.4	44
28	The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis?. Journal of Cystic Fibrosis, 2019, 18, 13-21.	0.3	32
29	Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients. International Journal of Antimicrobial Agents, 2019, 53, 84-88.	1.1	25
30	Detection and characterisation of bacteria causing lung infection in people with Cystic Fibrosis (CF) by surface-enhanced Raman spectroscopy (SERS). Access Microbiology, 2019, 1, .	0.2	2
31	Airway infection, systemic inflammation and lung clearance index in children and adults with cystic fibrosis. European Respiratory Journal, 2018, 51, 1701704.	3.1	10
32	Training in multiple breath washout testing for respiratory physiotherapists. Physiotherapy, 2018, 104, 61-66.	0.2	2
33	British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respiratory Research, 2018, 5, e000348.	1.2	37
34	Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. European Respiratory Journal, 2018, 52, 1800242.	3.1	69
35	Criteria required for an acceptable point-of-care test for UTI detection: Obtaining consensus using the Delphi technique. PLoS ONE, 2018, 13, e0198595.	1.1	10
36	Pathogen Eradication and Emerging Pathogens: Difficult Definitions in Cystic Fibrosis. Journal of Clinical Microbiology, 2018, 56, .	1.8	6

#	ARTICLE	IF	CITATIONS
37	Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000168.	1.2	15
38	Efficacy of <i>Pseudomonas aeruginosa</i> eradication regimens in bronchiectasis. <i>European Respiratory Journal</i> , 2017, 49, 1600851.	3.1	16
39	Novel freeze-dried DDA and TPGS liposomes are suitable for nasal delivery of vaccine. <i>International Journal of Pharmaceutics</i> , 2017, 533, 179-186.	2.6	22
40	Characterisation of eppin function: expression and activity in the lung. <i>European Respiratory Journal</i> , 2017, 50, 1601937.	3.1	5
41	Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 427-435.	1.1	43
42	Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with <i>Pseudomonas aeruginosa</i> . <i>European Respiratory Journal</i> , 2017, 50, 1601569.	3.1	20
43	Antibiotic susceptibility of planktonic- and biofilm-grown staphylococci isolated from implant-associated infections: should MBEC and nature of biofilm formation replace MIC?. <i>Journal of Medical Microbiology</i> , 2017, 66, 461-469.	0.7	38
44	Lung Clearance Index in Adults and Children With Cystic Fibrosis. <i>Chest</i> , 2016, 150, 1323-1332.	0.4	38
45	<i>Prevotella denticola</i> Lipopolysaccharide from a Cystic Fibrosis Isolate Possesses a Unique Chemical Structure. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 1732-1738.	1.2	11
46	Response. <i>Chest</i> , 2016, 150, 1413-1414.	0.4	4
47	MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis. <i>ERJ Open Research</i> , 2016, 2, 00064-2015.	1.1	18
48	Eradication and phenotypic tolerance of <i>Burkholderia cenocepacia</i> biofilms exposed to atmospheric pressure non-thermal plasma. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 446-450.	1.1	18
49	Production of extended-spectrum $\beta$ -lactamases and the potential indirect pathogenic role of <i>Prevotella</i> isolates from the cystic fibrosis respiratory microbiota. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 140-145.	1.1	59
50	"All illness is personal to that individual": a qualitative study of patients' perspectives on treatment adherence in bronchiectasis. <i>Health Expectations</i> , 2015, 18, 2477-2488.	1.1	21
51	Comparison of Microbiomes from Different Niches of Upper and Lower Airways in Children and Adolescents with Cystic Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0116029.	1.1	133
52	Microbiology review series: CF microbiology " Towards 2020 and beyond. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 289-290.	0.3	0
53	Predictors of adherence to treatment in bronchiectasis. <i>Respiratory Medicine</i> , 2015, 109, 838-845.	1.3	26
54	Reduced Bacterial Colony Count of Anaerobic Bacteria Is Associated with a Worsening in Lung Clearance Index and Inflammation in Cystic Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0126980.	1.1	49

#	ARTICLE	IF	CITATIONS
55	Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in <i>Prevotella</i> isolated from cystic fibrosis (CF) and non-CF patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2690-2698.	1.3	31
56	Dual functional ionic liquids as antimicrobials and plasticisers for medical grade PVCs. <i>RSC Advances</i> , 2014, 4, 8567.	1.7	26
57	Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. <i>Lancet, The</i> , 2014, 384, 703-713.	6.3	130
58	Lung Microbiota and Bacterial Abundance in Patients with Bronchiectasis when Clinically Stable and during Exacerbation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1118-1126.	2.5	258
59	Infection control strategies for preventing the transmission of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in nursing homes for older people. <i>The Cochrane Library</i> , 2013, , CD006354.	1.5	40
60	Improving Prescribing of Antibiotics in Long-term Care. <i>JAMA Internal Medicine</i> , 2013, 173, 682.	2.6	6
61	Antimicrobial prescribing in residential homes. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1781-1790.	1.3	33
62	Dual functional ionic liquids as plasticisers and antimicrobial agents for medical polymers. <i>Green Chemistry</i> , 2011, 13, 1527.	4.6	73
63	Antimicrobial prescribing in European nursing homes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1609-1616.	1.3	84
64	Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 995-1001.	2.5	431
65	In vitro activity of tea-tree oil against clinical skin isolates of methicillin-resistant and -sensitive <i>Staphylococcus aureus</i> and coagulase-negative staphylococci growing planktonically and as biofilms. <i>Journal of Medical Microbiology</i> , 2006, 55, 1375-1380.	0.7	66
66	Rapid Colorimetric Assay for Antimicrobial Susceptibility Testing of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1879-1881.	1.4	117
67	Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> complex isolates in vitro. <i>Journal of Microbiological Methods</i> , 2004, 57, 107-114.	0.7	8
68	Antimicrobial Susceptibility of Bacteria Isolated from Orthopedic Implants following Revision Hip Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 3002-3005.	1.4	111
69	Assessment of urinary tract biomaterial encrustation using a modified Robbins device continuous flow model. , 1997, 38, 87-93.		28